Drug intelligence / Profile preview

Treg-enriched donor cells (Dana-Farber Cancer Institute)

Development stage: Phase 1
Lead developer: Dana-Farber Cancer Institute
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

Treg-enriched donor cells (Dana-Farber) is an experimental cellular therapy developed by the Dana-Farber Cancer Institute for patients with relapsed/refractory or ultra-high-risk acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This therapy is a central component of an "immunosuppression-free" (IS-free) haploidentical hematopoietic cell transplantation (HCT) protocol. The process involves the ex vivo enrichment of regulatory T cells (Tregs) from a haploidentical (half-matched) related donor. These Tregs are infused into the patient to suppress graft-versus-host disease (GvHD) by modulating the immune response, which allows for the co-infusion of unmodified donor T cells that provide a potent graft-versus-leukemia (GvL) effect. This approach aims to eliminate the need for post-transplant pharmacological immunosuppression. The protocol also includes conditioning with chemotherapy and targeted radiation, such as Total Myeloid and Lymphoid Irradiation (TMLI).

Other names: regulatory T-cell enriched donor cell-Dana-Farber Cancer Institute-acute myeloid leukemia-myelodysplastic syndromesIS-free Treg-cell graft-engineered haplo transplantTreg-enriched donor cells

Beyond the preview

Go deeper on Treg-enriched donor cells (Dana-Farber Cancer Institute).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Treg-enriched donor cells (Dana-Farber Cancer Institute).

Explore the full profile